Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Emily Langlois

Nurse Practitioner Bowling Green, KY Nurse Practitioner

NPI 1922496090 CMS profile 10569360

825 2Nd Ave, Emergency Department, Bowling Green, KY 42101

Open in the dashboard

General payments

$9,790

569 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Langlois of Bowling Green, KY is reported in the CMS Open Payments database as having received $9,790 across 569 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,484 139
2024 General $2,676 156
2023 General $1,722 100
2022 General $1,645 99
2021 General $1,263 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Langlois
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Emily Langlois were reported at $2,484. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Emily Langlois Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,263 $135 $40–$426 $132
2022 $1,645 $152 $48–$470 $149
2023 $1,722 $166 $54–$529 $160
2024 $2,676 $173 $55–$556 $164
2025 $2,484 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $1,821 131 payments
  2. AbbVie, Inc. $1,341 70 payments
  3. UCB, Inc. $981 68 payments
  4. Novartis Pharmaceuticals Corporation $736 36 payments
  5. E.R. Squibb & Sons, L.L.C. $731 49 payments
  6. Janssen Biotech, Inc. $730 34 payments
  7. Lilly USA, LLC $539 32 payments
  8. Pfizer Inc. $500 25 payments
  9. AstraZeneca Pharmaceuticals LP $459 24 payments
  10. GlaxoSmithKline, LLC. $376 18 payments
  11. Other $1,576 82 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,501 564 payments
  2. Education $289 5 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,000 54 payments
  2. Enbrel $851 54 payments
  3. Otezla $740 51 payments
  4. ORENCIA $731 49 payments
  5. TREMFYA $717 33 payments
  6. Cimzia $653 46 payments
  7. COSENTYX $560 28 payments
  8. TALTZ $539 32 payments
  9. XELJANZ $500 25 payments
  10. SAPHNELO $437 23 payments
  11. Other $4,301 259 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,859

Median for Nurse Practitioner: 389

Drug cost

$744,850

Median for Nurse Practitioner: $21,885

Branded share of claims

25.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 35 $251,530
Orencia Clickject Abatacept Brand 34 $206,918
Benlysta Belimumab Brand 18 $86,140
Taltz Autoinjector Ixekizumab Brand 12 $81,975
Xeljanz Xr Tofacitinib Citrate Brand 12 $69,533
Hydroxychloroquine Sulfate Generic 683 $29,393
Methotrexate Methotrexate Sodium Brand 364 $7,513
Leflunomide Generic 68 $3,895
Celecoxib Generic 87 $2,232
Duloxetine Hcl Generic 70 $1,378

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$698,129

Of which drugs: $634,778

Medicare patients

268

Average age 70

Services billed

64,248

199 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Depression 28%
Ischemic heart disease 26%
Chronic kidney disease 20%
Heart failure 19%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 23 8,200 $276,304
Injection, golimumab, 1 mg, for intravenous use J1602 Office 24 13,150 $120,513
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 14 20,800 $75,323
Injection, methylprednisolone acetate, 1 mg J1010 Office 43 3,780 $384
Injection, ketorolac tromethamine, per 15 mg J1885 Office 21 157 $78

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $281
$281 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $271
$271 — —
Enbrel
  • Amgen Inc. $220
$220 35 —
RINVOQ
  • AbbVie, Inc. $201
$201 — —
ORENCIA
  • E.R. Squibb & Sons, L.L.C. $154
$154 34 8,200

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

569 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record